[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fDDQSy_5brIkqiK28skY_zuj55tnL7rdQ6p5-Q1yAnYc":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":32,"phaseBuckets":38,"rows":45},"SecuraBio",[4],24,false,1,5,1873,3,0,[14,17,19,21,23,25,28,30],{"name":15,"count":16},"Healthy",4,{"name":18,"count":16},"Small Lymphocytic Lymphoma",{"name":20,"count":16},"Chronic Lymphocytic Leukemia",{"name":22,"count":11},"Follicular Lymphoma",{"name":24,"count":11},"Lymphoma",{"name":26,"count":27},"Lymphoma, Small Lymphocytic",2,{"name":29,"count":27},"Indolent Non-Hodgkin Lymphoma",{"name":31,"count":8},"Hematologic Malignancy",[33],{"nctId":34,"briefTitle":35,"date":36,"intervention":37},"NCT06522737","A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed\u002FRefractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype","2028-02","Duvelisib",[39,40,41,42,43,44],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[46,82,100,232,340,370,392,414,432,457,475,493,511,529],{"intervention":47,"totalTrials":27,"cells":48},"Bendamustine",{"EARLY_PHASE1":49,"PHASE1":51,"PHASE2":53,"PHASE3":55,"PHASE4":78,"NA":80},{"trials":50,"activeCount":12},[],{"trials":52,"activeCount":12},[],{"trials":54,"activeCount":12},[],{"trials":56,"activeCount":8,"soonestReadout":36},[57,69],{"nctId":58,"briefTitle":59,"status":60,"phases":61,"primaryCompletion":62,"completion":62,"start":63,"enrollment":12,"conditions":64,"interventions":67},"NCT02576275","A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)","WITHDRAWN",[42],"2016-11","2015-12",[65,22,18,66],"Indolent Non-Hodgkin's Lymphoma","Marginal Zone Lymphoma",[37,68,47],"Rituximab",{"nctId":34,"briefTitle":35,"status":70,"phases":71,"primaryCompletion":36,"completion":72,"start":73,"enrollment":74,"conditions":75,"interventions":76},"RECRUITING",[42],"2028-12","2025-05-19",124,[24],[37,77,47],"Gemcitabine",{"trials":79,"activeCount":12},[],{"trials":81,"activeCount":12},[],{"intervention":77,"totalTrials":8,"cells":83},{"EARLY_PHASE1":84,"PHASE1":86,"PHASE2":88,"PHASE3":90,"PHASE4":96,"NA":98},{"trials":85,"activeCount":12},[],{"trials":87,"activeCount":12},[],{"trials":89,"activeCount":12},[],{"trials":91,"activeCount":8,"soonestReadout":36},[92],{"nctId":34,"briefTitle":35,"status":70,"phases":93,"primaryCompletion":36,"completion":72,"start":73,"enrollment":74,"conditions":94,"interventions":95},[42],[24],[37,77,47],{"trials":97,"activeCount":12},[],{"trials":99,"activeCount":12},[],{"intervention":37,"totalTrials":101,"cells":102},13,{"EARLY_PHASE1":103,"PHASE1":105,"PHASE2":107,"PHASE3":187,"PHASE4":217,"NA":219},{"trials":104,"activeCount":12},[],{"trials":106,"activeCount":12},[],{"trials":108,"activeCount":12},[109,119,130,142,151,160,170,179],{"nctId":110,"briefTitle":111,"status":112,"phases":113,"primaryCompletion":114,"completion":114,"start":115,"enrollment":116,"conditions":117,"interventions":118},"NCT02711852","A Long-term, Continued Treatment and Follow-up Study in Participants With Hematologic Malignancies Treated With Duvelisib (IPI-145)","COMPLETED",[41],"2020-05-04","2016-04",19,[31],[37],{"nctId":120,"briefTitle":121,"status":122,"phases":123,"primaryCompletion":124,"completion":124,"start":125,"enrollment":27,"conditions":126,"interventions":128},"NCT04193293","A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer","TERMINATED",[40,41],"2020-12-10","2020-06-01",[127],"Head and Neck Squamous Cell Carcinoma",[37,129],"Pembrolizumab",{"nctId":131,"briefTitle":132,"status":122,"phases":133,"primaryCompletion":134,"completion":135,"start":136,"enrollment":137,"conditions":138,"interventions":140},"NCT02391545","A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)",[40,41],"2017-01-17","2017-05","2014-12",55,[139],"CD20+ Follicular Lymphoma",[37,68,141],"Obinutuzumab",{"nctId":143,"briefTitle":144,"status":60,"phases":145,"primaryCompletion":146,"completion":147,"start":148,"enrollment":12,"conditions":149,"interventions":150},"NCT03370185","Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia \u002FSmall Lymphocytic Lymphoma",[41],"2020-06","2021-03","2018-02-12",[20,18],[37],{"nctId":152,"briefTitle":153,"status":112,"phases":154,"primaryCompletion":155,"completion":155,"start":156,"enrollment":157,"conditions":158,"interventions":159},"NCT01882803","A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin Lymphoma",[41],"2020-11-18","2013-06-17",129,[29],[37],{"nctId":161,"briefTitle":162,"status":112,"phases":163,"primaryCompletion":164,"completion":164,"start":165,"enrollment":166,"conditions":167,"interventions":169},"NCT03372057","A Study of Duvelisib in Participants With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)",[41],"2023-12-22","2018-02-22",156,[168],"Peripheral T-cell Lymphoma",[37,37,37],{"nctId":171,"briefTitle":172,"status":112,"phases":173,"primaryCompletion":174,"completion":174,"start":175,"enrollment":176,"conditions":177,"interventions":178},"NCT04038359","A Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Participants With Indolent Non-Hodgkin Lymphoma",[41],"2023-07-24","2019-09-24",103,[29],[37],{"nctId":180,"briefTitle":181,"status":60,"phases":182,"primaryCompletion":62,"completion":62,"start":63,"enrollment":12,"conditions":183,"interventions":184},"NCT02605694","Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed\u002FRefractory Follicular Lymphoma (FRESCO)",[41],[24],[37,68,185,186],"R-CHOP","Prednisone",{"trials":188,"activeCount":8,"soonestReadout":36},[189,198,202,206],{"nctId":190,"briefTitle":191,"status":122,"phases":192,"primaryCompletion":193,"completion":194,"start":195,"enrollment":101,"conditions":196,"interventions":197},"NCT02204982","Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma",[42],"2016-12","2017-03","2014-09",[22],[37,68],{"nctId":58,"briefTitle":59,"status":60,"phases":199,"primaryCompletion":62,"completion":62,"start":63,"enrollment":12,"conditions":200,"interventions":201},[42],[65,22,18,66],[37,68,47],{"nctId":34,"briefTitle":35,"status":70,"phases":203,"primaryCompletion":36,"completion":72,"start":73,"enrollment":74,"conditions":204,"interventions":205},[42],[24],[37,77,47],{"nctId":207,"briefTitle":208,"status":112,"phases":209,"primaryCompletion":210,"completion":211,"start":212,"enrollment":213,"conditions":214,"interventions":215},"NCT02004522","A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL\u002FSLL (DUO)",[42],"2017-05-19","2021-06","2013-11",319,[20,18],[37,216],"Ofatumumab",{"trials":218,"activeCount":12},[],{"trials":220,"activeCount":12},[221],{"nctId":222,"briefTitle":223,"status":122,"phases":224,"primaryCompletion":225,"completion":225,"start":226,"enrollment":27,"conditions":227,"interventions":229},"NCT04342117","Observational Trial of Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in CLL\u002FSLL and FL",[],"2020-12-31","2020-04-23",[26,24,228,20,22],"Lymphoma, Non-Hodgkin",[230,231],"duvelisib","PI3K inhibitor",{"intervention":233,"totalTrials":234,"cells":235},"IPI-145",10,{"EARLY_PHASE1":236,"PHASE1":238,"PHASE2":316,"PHASE3":326,"PHASE4":336,"NA":338},{"trials":237,"activeCount":12},[],{"trials":239,"activeCount":12},[240,250,259,267,277,286,296,306],{"nctId":241,"briefTitle":242,"status":112,"phases":243,"primaryCompletion":244,"completion":245,"start":246,"enrollment":247,"conditions":248,"interventions":249},"NCT01836861","IPI-145 ADME and Absolute Bioavailability Study",[40],"2013-04","2013-05","2013-03",6,[15],[233],{"nctId":251,"briefTitle":252,"status":112,"phases":253,"primaryCompletion":254,"completion":255,"start":256,"enrollment":176,"conditions":257,"interventions":258},"NCT02307461","Bioequivalence of Duvelisib and Food Effect on Pharmacokinetics of IPI-145",[40],"2015-08","2015-09","2014-11",[15],[233,233,233],{"nctId":260,"briefTitle":261,"status":122,"phases":262,"primaryCompletion":62,"completion":62,"start":263,"enrollment":11,"conditions":264,"interventions":266},"NCT02292225","Duvelisib With Obinutuzumab in Patients With CLL\u002FSLL Previously Treated With a BTKi (SYNCHRONY)",[40],"2015-02",[265,26],"Lymphocytic Leukemia, Chronic",[233,141],{"nctId":268,"briefTitle":269,"status":112,"phases":270,"primaryCompletion":212,"completion":271,"start":272,"enrollment":273,"conditions":274,"interventions":275},"NCT01947777","Phase 1 Study in Healthy Subjects to Evaluate the Effect of Rifampin on the Pharmacokinetics of IPI-145",[40],"2013-12","2013-10",14,[15],[233,276],"Rifampin",{"nctId":278,"briefTitle":279,"status":112,"phases":280,"primaryCompletion":281,"completion":272,"start":282,"enrollment":273,"conditions":283,"interventions":284},"NCT01925911","Phase 1 Study in Healthy Subjects to Evaluate the Effect of IPI-145 on the Pharmacokinetics of Midazolam",[40],"2013-09","2013-08",[15],[233,285],"Midazolam",{"nctId":287,"briefTitle":288,"status":122,"phases":289,"primaryCompletion":193,"completion":290,"start":291,"enrollment":292,"conditions":293,"interventions":295},"NCT01476657","A Phase 1 Study of Duvelisib in Patients With Advanced Hematologic Malignancies",[40],"2017-01","2011-10",210,[294],"Hematologic Malignancies",[233],{"nctId":297,"briefTitle":298,"status":112,"phases":299,"primaryCompletion":300,"completion":300,"start":301,"enrollment":302,"conditions":303,"interventions":305},"NCT01549106","IPI-145 Single Ascending, Multiple Ascending, Food Effect and Drug-Drug-Interaction Study",[40],"2012-02","2011-08",106,[304],"Healthy Volunteers",[233],{"nctId":307,"briefTitle":308,"status":112,"phases":309,"primaryCompletion":310,"completion":311,"start":312,"enrollment":6,"conditions":313,"interventions":315},"NCT02095587","Duvelisib in Hepatically Impaired Subjects Compared to Healthy Subjects",[40],"2014-07","2014-10","2014-03",[314],"Hepatic Impairment",[233],{"trials":317,"activeCount":12},[318],{"nctId":319,"briefTitle":320,"status":112,"phases":321,"primaryCompletion":136,"completion":263,"start":244,"enrollment":322,"conditions":323,"interventions":325},"NCT01851707","A Double-Blind Study Evaluating Duvelisib in Subjects With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate Alone",[41],322,[324],"Rheumatoid Arthritis",[233],{"trials":327,"activeCount":12},[328],{"nctId":329,"briefTitle":330,"status":112,"phases":331,"primaryCompletion":332,"completion":332,"start":271,"enrollment":333,"conditions":334,"interventions":335},"NCT02049515","A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL\u002FSLL Previously Enrolled in Study IPI-145-07",[42],"2020-06-12",99,[20,18],[233,216],{"trials":337,"activeCount":12},[],{"trials":339,"activeCount":12},[],{"intervention":68,"totalTrials":16,"cells":341},{"EARLY_PHASE1":342,"PHASE1":344,"PHASE2":346,"PHASE3":356,"PHASE4":366,"NA":368},{"trials":343,"activeCount":12},[],{"trials":345,"activeCount":12},[],{"trials":347,"activeCount":12},[348,352],{"nctId":131,"briefTitle":132,"status":122,"phases":349,"primaryCompletion":134,"completion":135,"start":136,"enrollment":137,"conditions":350,"interventions":351},[40,41],[139],[37,68,141],{"nctId":180,"briefTitle":181,"status":60,"phases":353,"primaryCompletion":62,"completion":62,"start":63,"enrollment":12,"conditions":354,"interventions":355},[41],[24],[37,68,185,186],{"trials":357,"activeCount":12},[358,362],{"nctId":190,"briefTitle":191,"status":122,"phases":359,"primaryCompletion":193,"completion":194,"start":195,"enrollment":101,"conditions":360,"interventions":361},[42],[22],[37,68],{"nctId":58,"briefTitle":59,"status":60,"phases":363,"primaryCompletion":62,"completion":62,"start":63,"enrollment":12,"conditions":364,"interventions":365},[42],[65,22,18,66],[37,68,47],{"trials":367,"activeCount":12},[],{"trials":369,"activeCount":12},[],{"intervention":216,"totalTrials":27,"cells":371},{"EARLY_PHASE1":372,"PHASE1":374,"PHASE2":376,"PHASE3":378,"PHASE4":388,"NA":390},{"trials":373,"activeCount":12},[],{"trials":375,"activeCount":12},[],{"trials":377,"activeCount":12},[],{"trials":379,"activeCount":12},[380,384],{"nctId":207,"briefTitle":208,"status":112,"phases":381,"primaryCompletion":210,"completion":211,"start":212,"enrollment":213,"conditions":382,"interventions":383},[42],[20,18],[37,216],{"nctId":329,"briefTitle":330,"status":112,"phases":385,"primaryCompletion":332,"completion":332,"start":271,"enrollment":333,"conditions":386,"interventions":387},[42],[20,18],[233,216],{"trials":389,"activeCount":12},[],{"trials":391,"activeCount":12},[],{"intervention":141,"totalTrials":27,"cells":393},{"EARLY_PHASE1":394,"PHASE1":396,"PHASE2":402,"PHASE3":408,"PHASE4":410,"NA":412},{"trials":395,"activeCount":12},[],{"trials":397,"activeCount":12},[398],{"nctId":260,"briefTitle":261,"status":122,"phases":399,"primaryCompletion":62,"completion":62,"start":263,"enrollment":11,"conditions":400,"interventions":401},[40],[265,26],[233,141],{"trials":403,"activeCount":12},[404],{"nctId":131,"briefTitle":132,"status":122,"phases":405,"primaryCompletion":134,"completion":135,"start":136,"enrollment":137,"conditions":406,"interventions":407},[40,41],[139],[37,68,141],{"trials":409,"activeCount":12},[],{"trials":411,"activeCount":12},[],{"trials":413,"activeCount":12},[],{"intervention":129,"totalTrials":8,"cells":415},{"EARLY_PHASE1":416,"PHASE1":418,"PHASE2":420,"PHASE3":426,"PHASE4":428,"NA":430},{"trials":417,"activeCount":12},[],{"trials":419,"activeCount":12},[],{"trials":421,"activeCount":12},[422],{"nctId":120,"briefTitle":121,"status":122,"phases":423,"primaryCompletion":124,"completion":124,"start":125,"enrollment":27,"conditions":424,"interventions":425},[40,41],[127],[37,129],{"trials":427,"activeCount":12},[],{"trials":429,"activeCount":12},[],{"trials":431,"activeCount":12},[],{"intervention":433,"totalTrials":8,"cells":434},"IPI-145, a PI3K Inhibitor",{"EARLY_PHASE1":435,"PHASE1":437,"PHASE2":439,"PHASE3":451,"PHASE4":453,"NA":455},{"trials":436,"activeCount":12},[],{"trials":438,"activeCount":12},[],{"trials":440,"activeCount":12},[441],{"nctId":442,"briefTitle":443,"status":112,"phases":444,"primaryCompletion":445,"completion":195,"start":446,"enrollment":447,"conditions":448,"interventions":450},"NCT01653756","A Phase 2a, Efficacy and Safety Study of Duvelisib in Mild Asthmatic Subjects",[41],"2014-08","2012-07",50,[449],"Asthma",[433],{"trials":452,"activeCount":12},[],{"trials":454,"activeCount":12},[],{"trials":456,"activeCount":12},[],{"intervention":185,"totalTrials":8,"cells":458},{"EARLY_PHASE1":459,"PHASE1":461,"PHASE2":463,"PHASE3":469,"PHASE4":471,"NA":473},{"trials":460,"activeCount":12},[],{"trials":462,"activeCount":12},[],{"trials":464,"activeCount":12},[465],{"nctId":180,"briefTitle":181,"status":60,"phases":466,"primaryCompletion":62,"completion":62,"start":63,"enrollment":12,"conditions":467,"interventions":468},[41],[24],[37,68,185,186],{"trials":470,"activeCount":12},[],{"trials":472,"activeCount":12},[],{"trials":474,"activeCount":12},[],{"intervention":186,"totalTrials":8,"cells":476},{"EARLY_PHASE1":477,"PHASE1":479,"PHASE2":481,"PHASE3":487,"PHASE4":489,"NA":491},{"trials":478,"activeCount":12},[],{"trials":480,"activeCount":12},[],{"trials":482,"activeCount":12},[483],{"nctId":180,"briefTitle":181,"status":60,"phases":484,"primaryCompletion":62,"completion":62,"start":63,"enrollment":12,"conditions":485,"interventions":486},[41],[24],[37,68,185,186],{"trials":488,"activeCount":12},[],{"trials":490,"activeCount":12},[],{"trials":492,"activeCount":12},[],{"intervention":276,"totalTrials":8,"cells":494},{"EARLY_PHASE1":495,"PHASE1":497,"PHASE2":503,"PHASE3":505,"PHASE4":507,"NA":509},{"trials":496,"activeCount":12},[],{"trials":498,"activeCount":12},[499],{"nctId":268,"briefTitle":269,"status":112,"phases":500,"primaryCompletion":212,"completion":271,"start":272,"enrollment":273,"conditions":501,"interventions":502},[40],[15],[233,276],{"trials":504,"activeCount":12},[],{"trials":506,"activeCount":12},[],{"trials":508,"activeCount":12},[],{"trials":510,"activeCount":12},[],{"intervention":285,"totalTrials":8,"cells":512},{"EARLY_PHASE1":513,"PHASE1":515,"PHASE2":521,"PHASE3":523,"PHASE4":525,"NA":527},{"trials":514,"activeCount":12},[],{"trials":516,"activeCount":12},[517],{"nctId":278,"briefTitle":279,"status":112,"phases":518,"primaryCompletion":281,"completion":272,"start":282,"enrollment":273,"conditions":519,"interventions":520},[40],[15],[233,285],{"trials":522,"activeCount":12},[],{"trials":524,"activeCount":12},[],{"trials":526,"activeCount":12},[],{"trials":528,"activeCount":12},[],{"intervention":231,"totalTrials":8,"cells":530},{"EARLY_PHASE1":531,"PHASE1":533,"PHASE2":535,"PHASE3":537,"PHASE4":539,"NA":541},{"trials":532,"activeCount":12},[],{"trials":534,"activeCount":12},[],{"trials":536,"activeCount":12},[],{"trials":538,"activeCount":12},[],{"trials":540,"activeCount":12},[],{"trials":542,"activeCount":12},[543],{"nctId":222,"briefTitle":223,"status":122,"phases":544,"primaryCompletion":225,"completion":225,"start":226,"enrollment":27,"conditions":545,"interventions":546},[],[26,24,228,20,22],[230,231]]